Jennifer R. Brown, MD, PhD, discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next-generation BTK inhibitor acalabrutinib monotherapy as treatment of patients with chronic lymphocytic leukemia.
Jennifer R. Brown, MD, PhD, director, Chronic Lymphocytic Lueukemia (CLL) Center, Dana-Farber Cancer Institute, and professor, Medicine, Harvard Medical School, discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next-generation Bruton’s kinase (BTK) inhibitor acalabrutinib (Calquence) monotherapy as treatment of patients with CLL.
The findings, which were presented during the 2020 American Society of Hematology (ASH) Annual Meeting, support what has been seen in the clinic, says Brown. The cardiovascular adverse events were reduced with acalabrutinib compared with ibrutinib (Imbruvica).
In Brown’s practice, she tends to favor acalabrutinib over ibrutinib for most patients. The next-generation BTK inhibitor should strongly be considered for patients with known cardiac risk factors, according to Brown, but head-to-head comparison data for 17p and 11q in patients with CLL are expected sometime in the next year.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More